Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by HighteawithIntrepidon Nov 17, 2017 4:44am
183 Views
Post# 26981964

RE:RE:RE:RE:RE:RE:If and when vs when

RE:RE:RE:RE:RE:RE:If and when vs whenPretty simple. PLI is trading at 50% and most of the others 
are up, top up the portfolio with an inheritance none of which went into PLI
and we are where we are. The English rules was a positive post by BIO.
 I think PL should have stated the SRAM deal was negotiated 
in US dollars and the strengthening Canadian dollar has reduced 
the amount receivable as of September 30th. I believe
the difference is about 5% less CDN cash receivable. Back to bed.
Bullboard Posts